Research programme: TrkA receptor antagonists - VM Discovery

Drug Profile

Research programme: TrkA receptor antagonists - VM Discovery

Alternative Names: VMD-902

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VM Discovery
  • Class Small molecules
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Inflammation; Neuropathic pain; Pancreatic cancer; Prostate cancer; Psoriasis; Vascular restenosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in USA
  • 08 Sep 2015 Purdue Pharma acquires the intellectual property rights of VM 902 and related compounds from VM Pharma
  • 21 Feb 2007 Preclinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top